Last reviewed · How we verify

IPV at 14 and fIPV at 22 weeks, RotaTeq

Centers for Disease Control and Prevention · FDA-approved active Biologic

IPV at 14 and fIPV at 22 weeks, RotaTeq is a vaccine Biologic drug developed by Centers for Disease Control and Prevention. It is currently FDA-approved for Prevention of poliomyelitis (IPV component), Prevention of rotavirus gastroenteritis (RotaTeq component).

IPV (inactivated poliovirus vaccine) and RotaTeq (rotavirus vaccine) stimulate the immune system to produce antibodies and cellular immunity against poliovirus and rotavirus, respectively, preventing infection and disease.

IPV (inactivated poliovirus vaccine) and RotaTeq (rotavirus vaccine) stimulate the immune system to produce antibodies and cellular immunity against poliovirus and rotavirus, respectively, preventing infection and disease. Used for Prevention of poliomyelitis (IPV component), Prevention of rotavirus gastroenteritis (RotaTeq component).

At a glance

Generic nameIPV at 14 and fIPV at 22 weeks, RotaTeq
SponsorCenters for Disease Control and Prevention
Drug classvaccine
ModalityBiologic
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

IPV contains chemically inactivated poliovirus particles that trigger humoral and cell-mediated immune responses without causing disease. RotaTeq is a live attenuated rotavirus vaccine administered orally that replicates in the intestinal tract, inducing mucosal and systemic immunity. Both vaccines work by priming the adaptive immune system to recognize and neutralize the respective pathogens upon natural exposure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about IPV at 14 and fIPV at 22 weeks, RotaTeq

What is IPV at 14 and fIPV at 22 weeks, RotaTeq?

IPV at 14 and fIPV at 22 weeks, RotaTeq is a vaccine drug developed by Centers for Disease Control and Prevention, indicated for Prevention of poliomyelitis (IPV component), Prevention of rotavirus gastroenteritis (RotaTeq component).

How does IPV at 14 and fIPV at 22 weeks, RotaTeq work?

IPV (inactivated poliovirus vaccine) and RotaTeq (rotavirus vaccine) stimulate the immune system to produce antibodies and cellular immunity against poliovirus and rotavirus, respectively, preventing infection and disease.

What is IPV at 14 and fIPV at 22 weeks, RotaTeq used for?

IPV at 14 and fIPV at 22 weeks, RotaTeq is indicated for Prevention of poliomyelitis (IPV component), Prevention of rotavirus gastroenteritis (RotaTeq component).

Who makes IPV at 14 and fIPV at 22 weeks, RotaTeq?

IPV at 14 and fIPV at 22 weeks, RotaTeq is developed and marketed by Centers for Disease Control and Prevention (see full Centers for Disease Control and Prevention pipeline at /company/centers-for-disease-control-and-prevention).

What drug class is IPV at 14 and fIPV at 22 weeks, RotaTeq in?

IPV at 14 and fIPV at 22 weeks, RotaTeq belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is IPV at 14 and fIPV at 22 weeks, RotaTeq in?

IPV at 14 and fIPV at 22 weeks, RotaTeq is FDA-approved (marketed).

What are the side effects of IPV at 14 and fIPV at 22 weeks, RotaTeq?

Common side effects of IPV at 14 and fIPV at 22 weeks, RotaTeq include Injection site pain, redness, or swelling (IPV), Fever, Irritability or fussiness, Diarrhea (RotaTeq), Vomiting (RotaTeq).

Related